Strategic financing will advance development of sac-TMT while Merck continues to progress its expansive pipeline.

The "Breast Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. The ...

Today, Full Sail University announced plans to unveil a state-of-the-art drone facility on its 210+ acre campus located in ...

CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to ...

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

The startup claims its medicines may be able to overcome the limitations of conventional antibody-drug conjugates by ...

Merck (MRK) announced that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences for the development of ...

Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

NEOK Bio, Inc., a biotechnology company focused on the development of novel antibody drug conjugates (ADCs) for improving ...

Merck (MRK) stock is in focus as the company secures $700M from Blackstone to advance cancer therapy sacituzumab tirumotecan ...

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into ...